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Novel grading system for quantification of
cystic macular lesions in Usher syndrome
Ieva Sliesoraityte1*, Tunde Peto2, Saddek Mohand-Said1 and Jose Alain Sahel1,3
Abstract
Background: To evaluate novel grading system used to quantify optical coherence tomography (OCT) scans for
cystic macular lesions (CML) in Usher syndrome (USH) patients, focusing on CML associated alterations in MOY7A
and USH2A mutations.
Methods: Two readers evaluated 76 patients’ (mean age 42 ± 14 years) data prospectively uploaded on Eurush
database. OCT was used to obtain high quality cross-sectional images through the fovea. The CML was graded as
none, mild, moderate or severe, depending on the following features set: subretinal fluid without clearly detectable
CML boundaries; central macular thickness; largest diameter of CML; calculated mean of all detectable CML; total
number of detectable CML; retinal layers affected by CML. Intra-and inter-grader reproducibility was evaluated.
Results: CML were observed in 37 % of USH eyes, while 45 % were observed in MYO7A and 29 % in USH2A cases.
Of those with CML: 52 % had mild, 22 % had moderate and 26 % had severe changes, respectively. CML were
found in following retinal layers: 50 % inner nuclear layer, 44 % outer nuclear layer, 6 % retinal ganglion cell layer.
For the inter-grader repeatability analysis, agreements rates for CML were 97 % and kappa statistics was 0.91
(95 % CI 0.83-0.99). For the intra-grader analysis, agreement rates for CML were 98 %, while kappa statistics was
0.96 (95 % CI 0.92-0.99).
Conclusions: The novel grading system is a reproducible tool for grading OCT images in USH complicated by CML,
and potentially could be used for objective tracking of macular pathology in clinical therapy trials.
Keywords: Cystic macular lesions, Grading system, Optical coherence tomography, Usher syndrome, Genotype,
Phenotype
Background
Usher syndrome (USH) is a rare autosomal recessive
group of disorders characterized by retinitis pigmentosa
(RP), sensorineural hearing loss and vestibular dysfunc-
tion. Three clinical types are distinguished (USH1, USH2
and USH3) and additional atypical subtypes have been
described associated with 10 causative genes and three
additional loci [1–5]. Hearing impairment is a first symp-
tom to develop in USH. Visual symptoms manifest as ret-
initis pigmentosa (RP), a progressive retinal dystrophy,
with rod and secondary cone photoreceptor dysfunction
and ultimate loss. USH is a clinically and genetically het-
erogeneous disorder, making diagnosis and treatment
challenging [6–9]. Previous studies categorized the
morphological retinal findings of USH patients, showing
that cystoid macula edema and/or cystic macular lesions
(CML) are the most common complications in RP asso-
ciated with USH (USH-RP) [10, 11]. CML has been
reported to be present in 8-56 % of all USH and/or RP pa-
tients [12–19].
Morphologically CML is characterized as a focal or
generalized retinal thickening due to accumulation of
fluid within retinal layers, which may lead to the formation
of a lamellar or full-thickness macular hole. Moreover, even
non-significant cystoid changes might contribute to a pro-
gressive impairment of visual acuity in RP, likely due to the
degenerative process affecting retinal layers [20]. The cen-
tral macula thickness (CMT) is assumed to be a potential
morphological end-point for evaluating safety and efficacy
of a treatment modality, which is aimed primarily for im-
proving macular photoreceptor cells associated structure
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and/or function. Thus, it is of a key importance to have a
sophisticated grading system for quantification of CML in
USH-RP associated with CML.
Even though CML is a frequent complication of RP
and despite of several attempts to grade CML [21, 22], a
need remains for an image grading protocol based on
optical coherence tomography (OCT) to assist clinicians
in describing all relevant aspects of an individual type of
CML in USH-RP cases. We propose a new CML grading
system for USH-RP patients, including comparative
evaluation of CML between USH types and most fre-
quent USH-associated genes, i.e. MYO7A and USH2A.
Such a grading system would allow evaluation of USH-
RP prognostic factors and treatment decisions in a very
detailed way.
Methods
Subjects and database
This prospective observational cohort study was con-
ducted according to the tenets of the Declaration of
Helsinki and received authorization from Ile-de-France V
ethical board committee for human research (June 4th
2013) and from the French regulation agency for medi-
cation (September 3rd 2013) (http://clinicaltrials.gov/ct2/
show/NCT01954953). The Eurush database (www.eurush-
database.org) was used where subjects’ data were uploaded
on a prospective manner. The participants were recruited
at the Centre Hospitalier National d’Ophtalmologie des
Quinze-Vingts, Paris, France. The study procedure was
fully explained to all patients, and their informed written
consent was obtained. Seventy six patients with a clinical
diagnosis of USH were enrolled (age 42 ± 14 years). The
inclusion criteria were: clinical characteristics for USH1,
USH2 and USH3 as defined by the Usher syndrome
consortium [23]; informed consent and agreement to
participate in the study. Exclusion criteria were: systemic
pathologies or severe ocular pathologies; systemic or top-
ical medication usage; otolaryngology pathologies which
could contaminate the results; unwillingness to provide a
blood sample for genetic test; unwilling and/or unable to
undergo the study procedures. In more details we ana-
lyzed two groups, i.e. having mutations in genes USH2A
andMYO7A.
Each patient underwent standard comprehensive oph-
thalmological examinations, which included assessment
of the medical and family history, best corrected visual
acuity (BCVA) using Early Treatment Diabetic Retinop-
athy Study (EDTRS), tonometry, slit-lamp biomicroscopy,
direct and indirect ophthalmoscopy, static and kinetic per-
imetry using standard III4e isopters (Haag Streit, Koeniz,
Switzerland). Full-field electroretinography (ERG) was
performed with the Espion system (Espion Diagnosys,
Littleton, MA), whereas multifocal electrophysiological
recordings were carried out using the VERIS 4.9.1 system
(Electro-Diagnostic Imaging, Inc., Redwood City). OCT
and fundus autofluorescence (AF) were carried out
using HRA II confocal scanning laser ophthalmoscope
(Heidelberg Engineering, Heidelberg, Germany).
Standard cystic macular lesions grading procedure
OCT image grading was performed in XV/XX reading
centre (Paris, France). High quality macula scans were
acquired using Spectralis HRA +OCT (Heidelberg En-
gineering, Dossenheim, Germany). The macular acquisi-
tion protocol consisted of 19 line raster fovea centered
scans with at least a 15° by 15° region. The standard file
transfer protocol was employed to transfer images in an-
onymous format to a local server. Five single scans lines,
i.e. foveal scan, two below and two above the fovea were
used for determining CML in both eyes. Both eyes were
checked for CML. Only one (right) eye high quality
cross-sectional image through the fovea was used for
further grading. If CML were not present in foveal line
scan but appeared in other 2 lines below or above the
fovea, the closest line to the fovea was used for grading.
The trained graders performed OCT image grading
using a novel grading system for CML quantification. In
addition, 3 randomly selected tomograms were provided
to each grader to test reproducibility. All reproducibility
testing were performed 5 weeks after initial grading to
avoid possible reader recall of the initial arbitration and
to monitor temporal variability. The intra-grader and
inter-grader reproducibility was calculated, in details de-
scribed elsewhere [24]. Scan quality was estimated de-
pending on presence/absence following features: fovea
non determinable on OCT, incorrect positioning, and
very poor saturation due to cataract and/or vitreous
strands and opacities.
The protocol used to define the CML included the
presence of cystoids spaces defined as hypo-reflective
zone visible on at least two views of the sequential line
scans in macula area. The boundaries of each CML were
manually marked using Adobe Photoshop CS5.5 version.
A grading protocol was defined covering all possible
morphological alterations and characteristic patterns
typically associated with CML, namely: 1. Subretinal
fluid without clearly detectable CML boundaries (Fs); 2.
CMT; 3. Largest diameter of CML (Dn); 4. Calculated
mean of all detectable CML (D); 5. Total number of de-
tectable CML (N); 6. Retinal layers affected by CML (L)
(Fig. 1). Hence, CML was graded as mild, moderate or
severe depending on above described features pattern
(Table 1).
Currently, there is no available standard CML grading
system and CMT is used for edema evaluation. Only for
comparative reasons with the literature data, we extin-
guished CMT criterion from CML grading system for
the more detailed analysis. Once the grading database
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was verified and closed, the grading and clinical data
were merged for the analysis.
Statistical analysis
Statistical analysis was carried out using SPSS software
(version 19.0, SPSS Inc., Chicago, USA). We analyzed
CML in the whole cohort and in two groups associated
with mutations in USH2A and MYO7A. Pearson correl-
ation (r) was used to assess the correlation between cen-
tral macular thickness and age in a whole cohort and
associated genes, namely USH2A and MYO7A. One-way
analysis of variance (ANOVA) was performed to detect
differences between CML severity in associated gene
USH2A and MYO7A. The percent agreement and the
kappa statistics were calculated as measures for categor-
ical variables (quality of scan and presence of CML).
Percent agreement was computed as the number of con-
cordant grading pairs divided by the total number of
grading pairs multiplied by 100. All numerical data are
presented here as arithmetic means ± standard deviation
(SD). A two side P value less than 0.05 was considered
statistically significant.
D2
D1
L
CMT
Fs+
N2N1
15°
0 °
Fovea
Fig. 1 The schematic grading of cystic macular lesions in optical coherence tomography images. Retinal cystic lesions were quantified through
the fovea line scan within to 15° eccentricity. Evaluated parameters were: total quantity of cystic macular lesions (N = N1 + N2 + […] + Nn);
averaged largest diameter of all cystic lesions (D = (D1 + D2 + […] + Dn)/n); layer affected by cystic lesions (L); presence/absence of foveal retinal
layer/-s swelling (Fs+/ Fs-), if boundaries of cystic lesions were not detectable (e.g. media opacities); central macular thickness (CMT)
Table 1 The grading system for the cystic macular lesions severity and selected tomograms examples in Usher syndrome patients.
A-B Mild: the right eye of 26 year male with mutation in USH2A:c.7595-3C > G+ c.7595-2144A > G, having less than 10 small size
cystic lesions and central macula thickness (CMT) within 200 μm (A), the right eye of 38 year male with mutation in USH2A: E767fs,
having less than 10 medium size cystic lesions (B); C-D Moderate: the right eye of 14 year female with mutation in MYO7A: L2186P *2,
having more than 10 medium size cystic lesions and CMT up to 300 μm (C), the right eye of 31 year male with mutation in
USH2A:T4337M + C717G, having up to 20 small and up to 10 medium size cystic lesions and one large diameter cyst (D); E-F severe:
the right eye of 35 year female with mutation in USH2A:V218E + G660R, having more than 10 medium size cystic lesions, more than
5 large and several extra large (E), the right eye of 24 year male with mutation in MYO7A:N1182K*2, having several extra large
diameter cystic lesion (F). * The presence of epiretinal membrane
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Results
Main clinical characteristics
Our cohort consisted of 76 patients, 41 (54 %) were
males. All 76 (100 %) patients were found to carry at
least one mutation, while 68/76 (89 %) of them carrying
two mutations in USH-associated genes. The methodology
used to detect mutations (complete exon sequencing) in
USH associated genes is described in details elsewhere [2].
The prevalence of mutations in USH-associated genes was
as following: 13/76 (17 %) MYO7A, 4/76 (5 %) CDH23,
2/76 (3 %) PCDH15, 1/76 (1 %) USH1C, 44/76 (58 %)
USH2A, 8/76 (11 %) VLGR1, 3/76 (4 %) CLRN1, and
1/76 (1 %) had mutations in VLGR1 and MYO7A
genes. The mean age was of 42 ± 14 years (range of
14 to 74 years). There was no statistically significant
difference in age between MYO7A and USH2A: 41 ± 15
(14 to 69) years for MYO7A and 44 ± 13 (23 to 74) years
for USH2A. The average BCVA for the whole cohort was
0.40 logMAR units (range,−0.1 to 1.5, Snellen equivalent
of 20/50), while 0.61 logMAR units (range 0.1 to 1.5,
Snellen equivalent of 20/80) forMYO7A and 0.34 logMAR
units (−0.1 to 1.5, Snellen equivalent of 20/40) for USH2A.
MYO7A patients tended to have worse BCVA compared
to USH2A, although the difference did not reach statisti-
cally significant level (p > 0.05).
Grading of optical coherence tomography scans
The OCT scans were graded using the novel CML grading
system (Table 1). Of the 76 USH patients, for 13 patients
OCTs were not performed due to the advanced stages of
USH affecting the ocular media: 2/13 (15 %) in MYO7A,
6/13 (46 %) in USH2A, and 5/13 (39 %) in other genes. Of
those with performed OCT, CML were present in 23/63
(37 %) cases. CML were found in 12/23 (52 %) males and
11/23 (48 %) females, without any evident gender prepon-
derance. We observed that USH1 (and MYO7A) tend to
have higher incidence of CML compared to USH2 (and
USH2A): 6/14 (43 %) in USH1 (and 5/11 (45 %) in
MYO7A) and 14/45 (31 %) in USH2 (and 11/38 (29 %) in
USH2A), respectively. The CML severity for a USH cohort
was as following: 12/23 (52 %) mild, 5/23 (22 %) moderate,
and 6/23 (26 %) severe. USH1 (and MYO7A) tend to have
more severe CML, while USH2 (and USH2A) tend to have
mild CML (Fig. 2a and b).
Analyzing retinal layers integrity, CML tended to affect
one retinal layer: 16/23 (70 %) monolayer vs 7/23 (30 %)
poly-layer (p < 0.05). Of those with monolayer involve-
ment, the inner nuclear layer (INL) was affected in 8/16
(50 %), outer nuclear layer (ONL) in 7/16 (44 %), and
the retinal ganglion cell layer (RGC) 1/16 (6 %) cases. Of
those with poly-layer involvement, the INL was affected
in 6/7 (86 %), ONL in 7/7 (100 %), RGC 2/7 (29 %) and
the inner plexiform layer (IPL) was affected in 2/7 (29 %)
cases. There was no statistically significant difference in
CML retinal layers predisposition between USH types or
USH-associated genes (Fig. 3a and b). When study cohort
was divided in four groups, those with monolayer CML,
i.e. in RGC, INL, ONL, and poly-layer CML, the mean
CMT was as following: 176 μm (RGC), 218 ± 57 μm
(INL), 166 ± 52 μm (ONL), and 332 ± 106 μm (poly-layer),
respectively. The more severe CML were observed in
cases affecting INL compared to other layers (p < 0.001).
CMT values tend to be higher in MYO7A group com-
pared to USH2A: 263 ± 91 μm and 212 ± 89 μm, respect-
ively, however this was not statistically significant. Linear
regression analysis showed a statistically significant asso-
ciation between CMT and age (at the time of exa-
mination) in USH1 and USH2 (r = −0.51, p = 0.01 and
r = −0.47, p = 0.01) and as following USH2A and
MYO7A (r = −0.58, p = 0.01 and r = −0.44, p = 0.01).
(Fig. 4a and b).
Quality assurance data for a novel grading system
The evaluation of the proposed system is done using
Eurush database estimating intra-grader and inter-grader
repeatability. The time to grade one tomogram with
a b
T
ot
al
 [
%
]
T
ot
al
 [
%
]
USH2
USH1
USH2A
MYO7A
Mild                   Moderate                   Severe
Central macular lesions severity [degree]  
Mild                    Moderate                   Severe
Central macular lesions severity [degree]  
Fig. 2 The prevalence of cystic macular lesions severity in Usher syndrome cases. The prevalence of cystic macular lesions in USH 1 and USH 2
a, the prevalence of cystic macular lesions in USH2A and MYO7A b
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CML required in averaged 5 min ± 1 min for the first
and 6 min ± 1 min for the second grader (not statistically
significant p > 0.05). The difference in mean CML diam-
eter was 2 μm± 1.5 μm between the two graders per-
formed grading of OCT scans. Reproducibility rates
were high for the categorical variables scan quality at the
fovea and CML. For the inter-grader repeatability ana-
lysis, agreements rates were 97 % (95 % CI 0.915-1.00)
and 95 % (95 % CI 0.89-1.00) for the scan quality at the
fovea and CML, respectively. The kappa statistics was
0.93 (95 % CI 0.85-1.00) and 0.91 (95 % CI 0.83-0.99) for
the scan quality at the fovea and CML, respectively. For
the intra-grader analysis, agreement rates were 96 %
(95 % CI 0.80-1.00) and 98 % (95 % CI 0.89-1.00) for the
scan quality at the fovea and CML, respectively. Like-
wise, kappa statistics was 0.91 (95 % CI 0.80-0.95) and
0.96 (95 % CI 0.92-0.99) for the scan quality at the fovea
and CML, respectively.
Fig. 3 Cystic macular lesions distribution by retinal layers distribution in Usher syndrome cases. The prevalence of CML by affected retinal layers
in USH1 vs USH2 a, the prevalence of CML by affected retinal layers in USH2A vs MYO7A b
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Discussion
In the present study, we established a novel grading sys-
tem that showed to be reliable and reproducible in our
reading centre for evaluating CML in USH-RP patients.
Our system consists of CML detection assessed by
trained graders, followed by evaluation of CML severity
and assessment of affected retinal layers. Using the novel
grading system OCT scans can be graded in a standard
manner in about 5 minutes.
To the best of our knowledge, there are limited refer-
ences in the literature regarding how to evaluate CML
severity in USH-RP cases. We found that using our
standard method, CML quantification gives a detailed
view on retinal morphological changes which is crucial
for disease progression monitoring and exact end-points
estimation. In addition, the incidence of CML was com-
pared within the most frequent USH-associated genes,
i.e. MYO7A and USH2A. In our cohort of 76 USH pa-
tients, CML rate was found to be 37 %, while in MYO7A
was of 45 % and USH2A was of 29 %. Almost half of
MYO7A cases were associated with CML, although a
statistically significant difference between MYO7A and
USH2A groups was not reached. In addition, MYO7A
cases tend to represent by severe CML, while USH2A
tend to have mild CML. So far no pathophysiological
studies were performed analyzing CML incidence differ-
ences in USH2A vs MYO7A. Thus, it definitely requires
more detailed investigations.
Our findings of 37 % having CML in OCT scans are
comparable to Hajali et al’s, namely 35 % USH2 and
39 % autosomal recessive RP patients had CML in OCT
scans [25, 26]. It must be acknowledged that there is a
great difference in the incidence of CML among the
various cohorts of RP patients, ranging from 8-15 %
[12, 16, 17] to 25-56 % [14, 15, 19, 25]. One reason
might be that ascertaining CML might vary due to race
and ethnicity differences. CML incidence rates are highly
dependent on RP inheritance pattern (recessive, dominant
or X linked) and so genotypic preponderance can also in-
fluence the results [11]. Some studies were very small
which can also lead to unstable estimates. Finally, the lack
of structured grading might also make ascertaining CML
difficult and unreliable.
In the current study we showed that eyes with CML
have 30 % greater CMT (235 ± 98 μm) compared to
those without CML (164 ± 59 μm). Gorovoy et al. [20]
also reported similar findings: 28 % of RP patients had
CML and half of them had increased central foveal
thickness (239 ± 10 μm). Some differences could be ex-
plained by differences in age between studies and the
variability in disease stage, in particularly the presence of
retinal atrophic changes. Our study clearly showed that
younger patients tended to have higher rates of CML
(r = −0.47, p = 0.01). In a large enough cohort, multiple
regression analysis where CML severity could be tested
against age and CMT would potentially provide new
insight into the natural disease history.
Additionally, we showed that CML tended to be
present in INL (50 %) and ONL (44 %). Makiyama et al.
[18] showed 27 % incidence of CML, while cystic lesions
were observed in the same layers as in our study, namely
INL (99 %) and ONL (28 %) and a minority in RGC.
Fakin et al. [19] observed 56 % CML in USH-RP pa-
tients, while CML were distributed in INL (60 %), INL
and ONL (33 %) and OPL (7 %). To the best of our
knowledge, there was no pathophysiological studies per-
formed so far analyzing CML affinity for the particular
retinal layers.
The natural course of CML associated with RP is in-
completely understood with several theories proposed.
Heckenlively et al. [26] proposed that CML might be a
result of an autoimmune process. The high incidence of
CML in INL and ONL could be explained by microglial
cells activation as a result of the autoimmune process
Fig. 4 The linear regression analysis between age and central macula thickness in all Usher cohort. The statistically significant negative association
was observed between CMT and patient age both in USH1 and USH2: r = −0.51 and r = −0.47 a; and as following in USH2A and MYO7A: r = −0.58
and r = −0.44 b
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[27 - 29]. An alternative hypothesis could be that CML
is a result of a breakdown in the retinal barrier at the
level of the retinal pigment epithelium which leads to a
fluid leakage in the macula. The breakdown of blood-
retinal barrier potentially results in accumulation of
plasma proteins which exert a high oncotic pressure in
the neural interstitium, which tends to produce intersti-
tial edema [30–32]. It is possible that both mechanisms
occur together [33, 34]. Lastly, it is possible that the
“cystic spaces” are actually due to apoptosis and there-
fore simply represent a space left from tissue loss [35].
Conclusion
A standard OCT-based retinal image evaluation in USH-
RP represents an urgent need both for clinicians and
scientists and calls for a reading centers focused of OCT
evaluation. The proposed grading system supplies a re-
producible tool for CML quantification in USH-RP, and
eventually could be used for objective tracking of macular
pathology in clinical trials. Using our grading system we
observed that CML is a common retinal complication in
USH-RP and showed that CML tended to be present in
both inner and outer nuclear layer. Moreover, we found
that MYO7A cases tend to have a higher CML incidence
rate and more severe CML compared to USH2A.
We describe for the first time a novel grading system for
CML evaluation that is based on expert knowledge and re-
quires trained personnel. In the future, the novel grading
system might be applied using semi-automatic image ana-
lysis for CML severity grading, taking into account func-
tional and/or other significant structural measures [36–40].
The system has a potential to be implemented in reading
centers as a sophisticated tool for retinal structure evalu-
ation in USH-RP. Surely, it would be directly applicable to
any CML in other retinal diseases (e.g. diabetic retinopathy,
age related macula edema) and aid treatment challenges in
other rare retinal degenerations.
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